تداخلات بيكساروتين

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (نشرة أسيتريتين، موانع الاستعمال)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (نشرة تتراسيكلين، التحذيرات)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (نشرة تريتينوين، موانع الاستعمال)

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (نشرة مينوسيكلين، التحذيرات والاحتياطات)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (نشرة بيكساروتين، التحذيرات والاحتياطات)

Patients with elevated vitamin A levels may be at increased risk. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (نشرة أورليستات، التداخلات الدوائية)

Patients with elevated vitamin A levels may be at increased risk. (نشرة إيفاكافتور، التحذيرات والاحتياطات)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (نشرة كلوريد الكالسيوم، التداخلات الدوائية)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (نشرة ميثوتريكسات، التداخلات الدوائية)

Monitor and replace thyroid hormone if needed. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (نشرة بيكساروتين، التحذيرات والاحتياطات)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (نشرة غلوكونات الكالسيوم، التداخلات الدوائية)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (نشرة فلوكونازول، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (نشرة بيكساروتين، التداخلات الدوائية)